Company research
RAPT Therapeutics, Inc.
CIK 1673772Updated Sep 27, 2026
Securities
Historical securities (1)
RAPT · NASDAQ · equity · closed Mar 2, 2026Name history
RAPT Therapeutics, Inc. · through May 15, 2026FLX Bio, Inc. · through Jan 2, 2019
RAPT price & chart
Historical security
This listing closed Mar 2, 2026. Live provider charts are shown only for current listings.
About the company
RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunologic diseases. Utilizing deep and proprietary expertise in immunology, RAPT develops novel molecules that are designed to modulate the critical immune responses underlying these diseases.
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 240,325,000Source | 173,329,000Source | 266,209,000Source | 198,636,000Source |
| Property, Plant and Equipment, NetUSD | 1,367,000Source | 2,448,000Source | 2,539,000Source | 2,741,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 169,735,000Source | 47,478,000Source | 38,946,000Source | 24,027,000Source |
| Assets, CurrentUSD | 235,236,000Source | 161,782,000Source | 252,694,000Source | 192,973,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,181,000Source | 2,920,000Source | 3,626,000Source | 3,319,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,333,000Source | 5,228,000Source | 6,940,000Source | — |
| Other Assets, NoncurrentUSD | 389,000Source | 3,871,000Source | 4,036,000Source | 2,922,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 50,421,000Source | 26,294,000Source | 21,043,000Source | 12,256,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 13,000Source | 3,000Source | 3,000Source | 3,000Source |
| Retained Earnings (Accumulated Deficit)USD | -614,547,000Source | -484,682,000Source | -367,884,000Source | -284,046,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 50,000Source | 103,000Source | -26,000Source | -206,000Source |
| Stockholders' Equity Attributable to ParentUSD | 189,904,000Source | 147,035,000Source | 245,166,000Source | 186,380,000Source |
| Additional Paid in Capital, Common StockUSD | 804,388,000Source | 631,611,000Source | 613,073,000Source | 470,629,000Source |
| Liabilities and EquityUSD | 240,325,000Source | 173,329,000Source | 266,209,000Source | 198,636,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 48,351,000Source | 21,836,000Source | 14,224,000Source | 9,595,000Source |
| Operating Lease, Liability, CurrentUSD | 2,422,000Source | 2,448,000Source | 2,171,000Source | — |
| Accounts Payable, CurrentUSD | 1,275,000Source | 5,176,000Source | 3,365,000Source | 1,999,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,070,000Source | 4,458,000Source | 6,819,000Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 9,597,000Source | 14,103,000Source | 8,656,000Source | 6,326,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 231,100,000Source | 158,900,000Source | 249,100,000Source | 189,700,000Source |
| Deferred Revenue, CurrentUSD | — | — | — | 1,016,000Source |
| Deferred Revenue, NoncurrentUSD | — | — | — | 511,000Source |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -129,865,000Source | -116,798,000Source | -83,838,000Source | -69,204,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 19,935,000Source | 17,091,000Source | 11,264,000Source | 9,952,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -83,297,000Source | -97,048,000Source | -70,771,000Source | -61,026,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 52,702,000Source | 104,133,000Source | -45,490,000Source | -81,347,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 122,000Source | 1,125,000Source | 845,000Source | 755,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 152,852,000Source | 1,447,000Source | 131,180,000Source | 141,482,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 122,257,000Source | 8,532,000Source | 14,919,000Source | -891,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | — | — | — | 0Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 19,935,000Source | 17,091,000Source | 11,264,000Source | 9,952,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 231,100,000Source | 158,900,000Source | 249,100,000Source | 189,700,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 0Source | 655,000Source | -627,000Source | -258,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | 0Source |
| General and Administrative ExpenseUSD | 28,884,000Source | 26,060,000Source | 20,240,000Source | 16,037,000Source |
| Net Income (Loss) Attributable to ParentUSD | -129,865,000Source | -116,798,000Source | -83,838,000Source | -69,204,000Source |
| Nonoperating Income (Expense)USD | 6,236,000Source | 10,264,000Source | 1,957,000Source | 5,000Source |
| Operating ExpensesUSD | 136,101,000Source | 127,062,000Source | 87,322,000Source | 73,022,000Source |
| Operating Lease, ExpenseUSD | 2,300,000Source | 2,300,000Source | 1,700,000Source | 2,300,000Source |
| Proceeds from Issuance of Common StockUSD | 8,957,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | 67,000Source | 500,000Source | 700,000Source | — |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Total RevenueUSD | — | 0Source | 1,527,000Source | 3,813,000Source |
| Operating Income (Loss)USD | -136,101,000Source | -127,062,000Source | -85,795,000Source | -69,209,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -129,865,000Source | -116,798,000Source | -83,838,000Source | -69,204,000Source |
| Net Income (Loss) Attributable to ParentUSD | -129,865,000Source | -116,798,000Source | -83,838,000Source | -69,204,000Source |
| Earnings Per Share, BasicUSD per share | -3.19Source | -3.05Source | -2.58Source | — |
| Earnings Per Share, DilutedUSD per share | -3.19Source | -3.05Source | -2.58Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 40,761,143Source | 38,338,161Source | 32,540,406Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 40,761,143Source | 38,338,161Source | 32,540,406Source | — |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | 1,203,000Source | 1,216,000Source | 1,047,000Source | 996,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 0Source | 655,000Source | -627,000Source | -258,000Source |
| General and Administrative ExpenseUSD | 28,884,000Source | 26,060,000Source | 20,240,000Source | 16,037,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -129,865,000Source | -116,798,000Source | -89,223,000Source | -66,464,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -3.19Source | -3.05Source | -2.58Source | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -3.19Source | -3.05Source | -2.58Source | — |
| Nonoperating Income (Expense)USD | 6,236,000Source | 10,264,000Source | 1,957,000Source | 5,000Source |
| Operating ExpensesUSD | 136,101,000Source | 127,062,000Source | 87,322,000Source | 73,022,000Source |
| Operating Lease, ExpenseUSD | 2,300,000Source | 2,300,000Source | 1,700,000Source | 2,300,000Source |
| Research and Development ExpenseUSD | 107,217,000Source | 101,002,000Source | 67,082,000Source | 56,985,000Source |
Filing attachments
d12800dex991.htm · 8-K · 2026-01-20
EX-99.1 4 d12800dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Stock-exchange announcement For media and investors only ─────────────────────────────── Issued: 20 January 2026, London UK GSK enters agreement to acquire RAPT Therapeutics Acquisition includes ozureprubart, a potentially best-in-class anti-IgE antibody, in development for prophylactic protection against food allergens Ozureprubart offers potential to protect against food allergy reactions with less frequent dosing c…
Read attachment ↗rapt-ex99_1.htm · 8-K · 2026-01-14
EX-99.1 2 rapt-ex99_1.htm EX-99.1 THE SCIENCE TO OVERCOME INFLAMMATION CORPORATE PRESENTATION JANUARY 2026 Disclaimer Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the development of ozureprubart (RPT904), including the expected timing of clinical trials and the availability of data therefrom and regulatory interactions; the therapeutic potential of…
Read attachment ↗rapt-ex99_1.htm · 8-K · 2025-11-06
EX-99.1 2 rapt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights • Initiated prestIgE Phase 2b trial of ozureprubart in food allergy • Announced positive topline data from Phase 2 trial in chronic spontaneous urticaria; results showed ozureprubart at both Q8W and Q12W dosing had comparable efficacy and safety to omalizumab at Q4W dosing • Completed $250 million public offering to strengthen balance sheet SOUTH S…
Read attachment ↗rapt-ex99_1.htm · 8-K · 2025-10-20
EX-99.1 2 rapt-ex99_1.htm EX-99.1 THE SCIENCE TO OVERCOME INFLAMMATION OCTOBER 20, 2025 Phase 2 Topline Results of RPT904 (JYB1904) in Chronic Spontaneous Urticaria Disclaimer Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the development of RPT904, including the expected timing of clinical trials and the availability of data therefrom; expectations …
Read attachment ↗rapt-ex99_1.htm · 8-K · 2025-08-07
EX-99.1 2 rapt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 RAPT Therapeutics Reports Second Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif. - August 7, 2025 - RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the second quarter and six …
Read attachment ↗rapt-ex99_1.htm · 8-K · 2025-07-08
EX-99.1 2 rapt-ex99_1.htm EX-99.1 THE SCIENCE TO OVERCOME INFLAMMATION CORPORATE PRESENTATION JULY 2025 Exhibit 99.1 Disclaimer Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the development of RPT904, including the expected timing of clinical trials and the availability of data therefrom and regulatory interactions; the therapeutic potential of RPT9…
Read attachment ↗